
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

ZeNix trial shows effectiveness of BPaL regimen for drug-resistant TB

01 September 2022 | News

The effectiveness can be maintained with reduced dosing of Linezolid



The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen. Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid. The results from the trial, which was led by TB Alliance, a global non-profit TB drug developer, were published in the New England Journal of Medicine.

A government-led study of the regimen in India called mBPaL commenced in October 2021 and is now enrolling patients at three sites out of a planned 11. It is scheduled to reach its primary completion in 2023 after enrolling 400 patients.